Monitoring cartilage loss in the hands and wrists in rheumatoid arthritis with magnetic resonance imaging in a multi-center clinical trial: IMPRESS (NCT00425932)
- 4k Downloads
Magnetic resonance imaging (MRI) is increasingly being used in clinical trials of rheumatoid arthritis (RA) because of its superiority over x-ray radiography (XR) in detecting and monitoring change in bone erosion, osteitis and synovitis. However, in contrast to XR, the MRI scoring method that was used in most clinical trials did not include cartilage loss. This limitation has been an obstacle to accepting MRI as a potential alternative to XR in clinical trials. Cross-sectional studies have shown MRI to be sensitive for cartilage loss in the hands and wrist; although, longitudinal sensitivity to change has not yet been confirmed. In this study we examined the ability of MRI to monitor change in cartilage loss in patients with RA in a multi-site clinical trial setting.
Thirty-one active RA patients from a clinical trial (IMPRESS) who were randomized equally into treatment with either rituximab + methotrexate or placebo + methotrexate had MRI of the dominant hand/wrist at baseline, 12 weeks and 24 weeks at 3 clinical sites in the US. Twenty-seven of these patients also had XR of both hands/wrists and both feet at baseline and 24 weeks. One radiologist scored all XR images using the van der Heijde-modified Sharp method blinded to visit order. The same radiologist scored MR images for cartilage loss using a previously validated 9-point scale, and bone erosion using the Outcome Measures in Rheumatology Clinical Trials (OMERACT) RA MRI Score (RAMRIS) blinded to visit order and XR scores. Data from the two treatment arms were pooled for this analysis.
Mean MRI cartilage score increased at 12 and 24 weeks, and reached statistical significance at 24 weeks. XR total Sharp score, XR erosion score and XR joint-space narrowing (JSN) score all increased at 24 weeks, but only XR total Sharp score increased significantly.
To our knowledge, this is the first publication of a study demonstrating MRI's ability to monitor cartilage loss in a multi-site clinical trial. Combined with MRI's established performance in monitoring bone erosions in RA, these findings suggest that MRI may offer a superior alternative to XR in multi-site clinical trials of RA.
KeywordsMagnetic Resonance Imaging Rheumatoid Arthritis Denosumab Bone Erosion Cartilage Loss
cyclic citrullinated peptide
disease activity score
erythrocyte sedimentation rate
magnetic resonance imaging
Outcome Measures in Rheumatology
rheumatoid arthritis magnetic resonance imaging score
longitudinal magnetic spin relaxation time
MRI is increasingly being used in clinical trials of rheumatoid arthritis (RA) because of its superiority over conventional radiography (XR) in detecting and monitoring change in bone erosion, osteitis and synovitis [1, 2, 3, 4, 5]. Moreover, recent trends in RA research have made XR increasingly impractical as a tool for monitoring disease progression and treatment response. These trends include 1) a shift from conventional placebo-controlled study designs to add-on and active-comparator studies, which require more patients and longer follow-up intervals to discriminate change; 2) the ethical imperative to provide early rescue-therapy to patients showing poor clinical response, which makes detecting structural change quickly a critical need; and 3) a decreasing supply of RA patients suitable for and willing to participate in randomized, controlled studies . As a consequence, no active-comparator trials using XR have been published thus far. Greater sensitivity of MRI to detect change in structural damage, and the ability to demonstrate osteitis and synovitis, provides probative information in less time and with fewer patients than is possible with XR. This has been demonstrated in several recently reported randomized, controlled clinical trials using MRI [1, 2, 3, 4, 5]. However, the MRI scoring method used in these studies, the Outcome Measures in Rheumatology (OMERACT) RA MRI score (RAMRIS) , did not include assessment of cartilage loss or joint-space narrowing (JSN). This limitation has been an obstacle to substituting MRI for XR in clinical trials, as articular cartilage loss is at least as important, if not more, as bone erosion in determining long-term disability in RA , and suppressing bone erosion does not always ensure that cartilage loss has been suppressed as well .
Cross-sectional studies have shown MRI to be sensitive for cartilage loss in the hand and wrist, and to correlate well with JSN on XR . However, the longitudinal sensitivity of MRI to detect change in cartilage loss has not yet been confirmed. In this study we monitored change in cartilage loss using conventional 1.5 Tesla (T) MRI in a multi-site clinical trial of patients with active RA.
Materials and methods
The first 31 patients with active RA (disease duration <5 years) enrolled in a multi-center clinical trial, Impact of Rituximab on Magnetic Resonance Imaging Evidence of Synovitis and Bone Lesions in Patients With Moderate or Severe Rheumatoid Arthritis (IMPRESS), who were randomized equally to treatment with either rituximab + methotrexate or placebo + methotrexate and had MRI of one hand and wrist at baseline, 12 weeks and 24 weeks using the standardized imaging protocol as described below, were included in this analysis. Twenty-seven of these patients also had standardized XR of both hands/wrists and both feet at baseline and 24 weeks. Four of the original 31 patients were missing either baseline or 24-week XR, and therefore were excluded from the XR analysis. The study protocol underwent institutional board review and received ethical approval by The Oklahoma Medical Research Foundation Internal Review Board and the Western Institutional Review Board, and all patients provided informed consent to participate in the study.
MRI erosion score and MRI cartilage score from each location in each study patient were summed to determine the MRI total erosion score and MRI total cartilage score at each time point. The maximum possible MRI total erosion score was 250. The maximum possible MRI total cartilage score was 100. MRI total erosion score and MRI total cartilage score were combined to derive the MRI total damage score for each patient at each time point. MRI total damage score was corrected for differences in the scales for MRI erosion score and MRI cartilage score, such that MRI total damage score = MRI total erosion score + (2.5 × MRI total cartilage score). The maximum possible MRI total damage score was thus 500. All analyses were based on these patient-level total scores.
Each of the two hands/wrists and feet of the 27 patients included in the XR analysis were radiographed separately on high-resolution 10 × 12 inch, single-emulsion, single screen film, using standardized positioning with a template. Hands/wrists were exposed posterior-anteriorly with the beam centered between the second and third MCP joints and perpendicular to the cassette. Radiographs were digitized to a pixel size of 100 mm at 12 bits per pixel. One radiologist (CP) scored all images, blinded to visit order and MRI results, for erosion and JSN using the van der Heijde-modified Sharp method .
Statistical significance of change in XR or MRI score from baseline to 12 weeks or 24 weeks was assessed using the two-sided t-test, with P = 0.05 as the cutoff for significance. Data from the two treatment arms were pooled for this analysis in order to maintain blinding to treatment, as the study was still ongoing.
Baseline characteristics of the patients were as follows: mean disease duration was <5 years; mean age was 42.2 years; 24 patients were women; 7 patients were men; mean disease duration was 21 months; 84% of patients were rheumatoid factor (RF)-positive; 65% were anti- cyclic citrullinated peptide (CCP)-positive; mean disease activity score (DAS)28 erythrocyte sedimentation rate (ESR) was 6.74.
Cross-sectional studies  have shown MRI to be sensitive to cartilage loss and JSN in RA, but to our knowledge this is the first publication of a study demonstrating the ability of MRI to monitor longitudinal change in cartilage loss in a time-blinded, multi-site clinical trial.
Significant progression of cartilage loss was demonstrated in this study within 24 weeks with only a single hand/wrist of 31 patients. Moreover, combining total cartilage score with total erosion score allowed determination of a MRI total damage score (Figure 7), analogous to that used in XR Sharp scoring . Progression of bone erosion and JSN in these patients was confirmed on XR, but statistical significance with XR was reached only for total sharp score by 24 weeks and only when bilateral hands, wrists and feet were included in the analysis.
Including cartilage loss in MRI assessment of RA is important because this feature of joint destruction does not always follow the same pattern of response to therapy as bone erosion does. Indeed, separating JSN and bone erosion was a fundamental innovation introduced in XR Sharp scoring , over global scoring methods, such as the Larson method . This disconnect between cartilage loss and bone erosion is illustrated in the randomized, controlled trial of denosumab, reported by Cohen et al. , in which, 227 patients with established RA were treated with either placebo plus methotrexate, or one of two doses of denosumab plus methotrexate, and followed longitudinally with XR (van der Heijde-Sharp erosion and JSN scoring) and MRI (RAMRIS erosion scoring). Whereas both RAMRIS and XR Sharp scoring showed denosumab to have strong erosion-suppressing effects, XR showed denosumab to have no effect on preventing JSN. Had only RAMRIS been used, the lack of efficacy on cartilage loss would not have been detected.
Accordingly, the OMERACT MRI Working Group, which originally developed RAMRIS, recently proposed adding a JSN component . The proposed MRI-JSN score uses a five-point scale similar but not identical to the van der Heijde Sharp XR JSN scale, and was shown to correlate with XR scoring cross-sectionally. McQueen et al.  also compared MRI to XR using a five-point scale to assess the wrists of 38 patients with RA and 22 control subjects. Although the joints evaluated by MRI and XR in their study were not exactly the same as those in either the van der Heijde-modified or the Genant-modified Sharp XR methods, correlations between the MRI cartilage score in the wrist and total XR JSN score were high in the same wrist (0.61 to 0.74) and in both hands, wrists and feet (0.68 to 0.78).
The nine-point MRI cartilage score  used in this study was modeled after the Genant-modified Sharp XR JSN score , which has been used in multiple clinical trials to gain regulatory approval of structure-modifying therapies, including abatacept , rituximab  and tocilizumab . Since the nine-point MRI scale contains more increments than five-point scales, it may have an advantage in terms of sensitivity to change; however, this has not been tested directly. Direct comparisons of the five-point van der Heijde-modified Sharp and nine-point Genant-modified Sharp XR JSN scoring methods, however, found both methods to have the same discriminative power for XR detection of change in JSN over time, and between treatment arms [18, 19]. Because only a single reading of the images was performed in this study, the intra-reader and inter-reader variability of the nine-point MRI cartilage score is not known.
That MRI is good at monitoring cartilage loss in RA is not surprising. First, the MRI tomographic viewing perspective obviates projection of the rims of the concave articular surfaces of joints over the joint space, which can mimic JSN on conventional radiographs (Figure 6) . Additionally, ligamentous laxity/rupture and interposition of synovial tissue or joint effusion between articular surfaces can decrease the accuracy of XR JSN as a measure of cartilage loss (Figure 5). Thus, the ability of MRI to visualize articular cartilage directly rather than only on the basis of the width of the space between opposing articular cortices is a substantial advantage [21, 22, 23, 24, 25]. The MRI protocol used in this study is the same as that used for monitoring bone erosion with RAMRIS in many other clinical trials of RA [1, 2, 3, 4, 5]. Thus, MRI protocols do not need to be expanded in order to add MRI cartilage score to assessments of joint damage.
Fat-suppressed, T1-weighted, three-dimensional, gradient-echo scans have been shown to delineate articular cartilage accurately in various joints, including the MCPs , and are commercially available on all clinical MRI systems operating at magnetic field strengths of 1.0 T or higher. Systems operating at lower field strengths currently have difficulty with this technique because of limitations in spectral fat suppression or selective water excitation. Selective fat suppression or water excitation is important for increasing T1 contrast between cartilage and adjacent joint fluid or subchondral bone (marrow fat) and for eliminating chemical-shift effects , which distort cartilage-bone interfaces and can simulate cartilage thinning and JSN. Increasing receiver bandwidth can reduce chemical shift, but this reduces the signal-to-noise ratio of the images, and does not completely eliminate the problem.
In conclusion, the findings presented in this study, taken in combination with those from prior studies validating cartilage assessment with MRI against JSN scoring with XR, suggest that MRI may offer a superior alternative to XR in multi-site clinical trials of RA. With the recent shift towards active-comparator study designs, which require longer study durations and more patients to demonstrate therapeutic superiority, and the increasing difficulty in recruiting RA patients into clinical trials, there is a growing need for more sensitive methods, such as MRI, to offset the escalating costs, patient exposure and logistical challenges associated with these trends.
MRI and XR images were provided by Genentech Inc.
- 1.Peterfy C, Olech E, Gaylis N, Valenzuela G, DiCarlo J, Countryman P, J M: Comparison of 1.5T whole-body MRI and 0.2T extremity MRI for monitoring rheumatoid arthritis in a multi-site clinical trial (IMPRESS). Ann Rheum Dis. 2011, 70: 368-Google Scholar
- 2.Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, van der Heijde D, Zhou L, Tsuji W, Newmark R: Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008, 58: 1299-1309. 10.1002/art.23417.CrossRefPubMedGoogle Scholar
- 3.Genovese MC, Kavanaugh A, Weinblatt ME, Peterfy C, DiCarlo J, White ML, O'Brien M, Grossbard EB, Magilavy DB: An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum. 2011, 63: 337-345. 10.1002/art.30114.CrossRefPubMedGoogle Scholar
- 4.Conaghan P, Durez P, Alten R, Burmester G, Tak PP, Klareskog L, Gaillez C, Le Bars M, Zhou X, Peterfy C: Impact of abatacept on synovitis and structural damage in MTX-inadequate responders with active RA: a randomized, controlled magnetic resonance imaging (MRI) pilot trial [abstract]. Arthritis Rheum. 2010, 62: S759-Google Scholar
- 5.Peterfy C, Haraoui B, Durez P, Kaushik P, Kupper H: Decreased incidence of synovitis, osteitis and erosion in early RA patients treated with adalimumab plus methotrexate compared to those with methotrexate alone: high-field MRI analysis from OPTIMA [abstract]. Arthritis Rheum. 2010, 62: S51-Google Scholar
- 6.O'Dell JR, Weinblatt ME, Colbert RA, Bathon J, Carter R, Cohen S, Curtis J, Cush J, Daikh D, Genovese M, Hardin J, Kavanaugh A, Keystone E, Kremer J, Mikuls TR, Moreland L, Nikolov N, Okada SP, Saag KG, Serrate-Sztein S, Solomon D, St Clair EW, Strand V, Woodcock J: American College of Rheumatology Clinical Trial Priorities and Design Conference, July 22-23, 2010. Arthritis Rheum. 2011, 63: 2151-2156.CrossRefGoogle Scholar
- 7.Ostergaard M, Peterfy C, Conaghan P, McQueen F, Bird P, Ejbjerg B, Shnier R, O'Connor P, Klarlund M, Emery P, Genant H, Lassere M, Edmonds J: OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. J Rheumatol. 2003, 30: 1385-1386.PubMedGoogle Scholar
- 9.Peterfy CG, Dion E, Miaux Y, WHite D, Lu Y, Zhao S, Jiang Y, Sack K, Stevens M, Fey K, Tayefeh F, Majumdar S, Stevens R, Van der Auwera P, Genant HK: Comparison of MRI and radiography for monitoring erosive changes in rheumatoid arthritis [abstract]. Proceedings of the 6th Meeting of the International Society for Magnetic Resonance in Medicine. 1998, S1: 458-Google Scholar
- 12.Genant HK, Peterfy CG, Westhovens R, Becker JC, Aranda R, Vratsanos G, Teng J, Kremer JM: Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis. 2008, 67: 1084-1089. 10.1136/ard.2007.085084.PubMedCentralCrossRefPubMedGoogle Scholar
- 14.Larson A, Dale K, Eck M: Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol [Diagn] (Stockh). 1977, 18: 481-491.Google Scholar
- 15.Ostergaard M, Boyesen P, Eshed I, Gandjbakhch F, Lillegraven S, Bird P, Foltz V, Boonen A, Lassere M, Hermann KG, Anandarajah A, Dohn UM, Freeston J, Peterfy CG, Genant HK, Haavardsholm EA, McQueen FM, Conaghan PG: Development and preliminary validation of a magnetic resonance imaging joint space narrowing score for use in rheumatoid arthritis: potential adjunct to the OMERACT RA MRI scoring system. J Rheumatol. 2011, 38: 2045-2050. 10.3899/jrheum.110422.CrossRefPubMedGoogle Scholar
- 16.Keystone E, Emery P, Peterfy CG, Tak PP, Cohen S, Genovese MC, Dougados M, Burmester GR, Greenwald M, Kvien TK, Williams S, Hagerty D, Cravets MW, Shaw T: Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis. 2009, 68: 216-221. 10.1136/ard.2007.085787.CrossRefPubMedGoogle Scholar
- 17.Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, Ambs P, Fleischmann R: Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011, 63: 609-621. 10.1002/art.30158.CrossRefPubMedGoogle Scholar
- 18.Peterfy CG, Wu C, Szechinski J, DiCarlo JC, Lu Y, Genovese M, Strand V, Genant HK: Comparison of the Genant-modified Sharp and van der Heijde-modified Sharp scoring methods for radiographic assessment of the hands, wrists and feet in rheumatoid arthritis. Int J Clin Rheumatol. 2011, 6: 15024-CrossRefGoogle Scholar
- 19.Genovese MC, Peterfy CG, Emery P, Keystone E, DiCarlo JC, Tak PP, Hagerty DT, Cravets M, Shaw T: Evaluation of joint damage in RA patients treated with rituximab: comparison of Genant- and van der Heijde-modified Sharp radiographic scoring [abstract]. Arthritis Rheum. 2008, 58: S369-Google Scholar
- 20.Peterfy C, Li J, Zaim S, Duryea J, Lynch J, Miaux Y, Yu W, Genant HK: Comparison of fixed-flexion positioning with fluoroscopic semi-flexed positioning for quantifying radiographic joint-space width in the knee: test-retest reproducibility. Skeletal Radiol. 2003, 32: 128-132. 10.1007/s00256-002-0603-z.CrossRefPubMedGoogle Scholar
- 22.Peterfy CG, van Dijke CF, Lu Y, Nguyen A, Connick TJ, Kneeland JB, Tirman PF, Lang P, Dent S, Genant HK: Quantification of the volume of articular cartilage in the metacarpophalangeal joints of the hand: accuracy and precision of three-dimensional MR imaging. Am J Roentgenol. 1995, 165: 371-375. 10.2214/ajr.165.2.7618560.CrossRefGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.